FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1878449863> ?p ?o ?g. }

• W1878449863 endingPage "380" @default.
• W1878449863 startingPage "368" @default.
• W1878449863 abstract "// Noemi Perez-Janices 1 , Idoia Blanco-Luquin 1 , Maria Teresa Tuñón 2 , Edurne Barba-Ramos 2 , Berta Ibáñez 3, 4 , Idoya Zazpe-Cenoz 5 , Maria Teresa Martinez-Aguillo 6 , Berta Hernandez 6 , Enrique Martínez-Lopez 7 , Agustin F. Fernández 8 , Maria Roasario Mercado 2 , Teresa Cabada 9 , David Escors 3 , Diego Megias 10 , David Guerrero-Setas 1 1 Cancer Epigenetics Group, Navarrabiomed-Fundación Miguel Servet, Navarra, Spain 2 Department of Pathology Section A, Complejo Hospitalario de Navarra, Navarra Health Service, Navarra, Spain 3 Navarrabiomed-Fundación Miguel Servet, Navarra, Spain 4 Red de Evaluación en Servicios Sanitarios y Enfermedades Crónicas (REDISSEC), Navarra, Spain 5 Department of Neurosurgery, Complejo Hospitalario de Navarra, Navarra Health Service, Navarra, Spain 6 Department of Medical Oncology, Complejo Hospitalario de Navarra, Navarra Health Service, Navarra, Spain 7 Department of Radiation Oncology, Complejo Hospitalario de Navarra, Navarra Health Service, Navarra, Spain 8 Cancer Epigenetics Laboratory, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), HUCA, Universidad de Oviedo, Asturias, Spain 9 Department of Radiology, Complejo Hospitalario de Navarra, Navarra Health Service, Navarra, Spain 10 Confocal Microscopy Core Unit, Spanish National Cancer Research Centre, Madrid, Spain Correspondence to: D. Guerrero-Setas, e-mail: dguerres@navarra.es Keywords: Brain tumors, EPB41L3, DNA methylation, prognosis, RASSF2, TSP-1 Received: August 05, 2014      Accepted: November 12, 2014      Published: January 24, 2015 ABSTRACT Hypermethylation of tumor suppressor genes is one of the hallmarks in the progression of brain tumors. Our objectives were to analyze the presence of the hypermethylation of EPB41L3 , RASSF2 and TSP-1 genes in 132 diffuse gliomas (astrocytic and oligodendroglial tumors) and in 10 cases of normal brain, and to establish their association with the patients’ clinicopathological characteristics. Gene hypermethylation was analyzed by methylation-specific-PCR and confirmed by pyrosequencing (for EPB41L3 and TSP-1 ) and bisulfite-sequencing (for RASSF2 ). EPB41L3 , RASSF2 and TSP-1 genes were hypermethylated only in tumors (29%, 10.6%, and 50%, respectively), confirming their cancer-specific role. Treatment of cells with the DNA-demethylating-agent 5-aza-2′-deoxycytidine restores their transcription, as confirmed by quantitative-reverse-transcription-PCR and immunofluorescence. Immunohistochemistry for EPB41L3 , RASSF2 and TSP-1 was performed to analyze protein expression; p53, ki-67, and CD31 expression and 1p/19q co-deletion were considered to better characterize the tumors. EPB41L3 and TSP-1 hypermethylation was associated with worse ( p = 0.047) and better ( p = 0.037) prognosis, respectively. This observation was confirmed after adjusting the results for age and tumor grade, the role of TSP-1 being most pronounced in oligodendrogliomas ( p = 0.001). We conclude that EPB41L3, RASSF2 and TSP-1 genes are involved in the pathogenesis of diffuse gliomas, and that EPB41L3 and TSP-1 hypermethylation are of prognostic significance." @default.
• W1878449863 created "2016-06-24" @default.
• W1878449863 creator A5013933481 @default.
• W1878449863 creator A5021788061 @default.
• W1878449863 creator A5026137617 @default.
• W1878449863 creator A5029195466 @default.
• W1878449863 creator A5037828387 @default.
• W1878449863 creator A5053377466 @default.
• W1878449863 creator A5059286400 @default.
• W1878449863 creator A5062071343 @default.
• W1878449863 creator A5063726212 @default.
• W1878449863 creator A5065387105 @default.
• W1878449863 creator A5066802040 @default.
• W1878449863 creator A5078601026 @default.
• W1878449863 creator A5080540302 @default.
• W1878449863 creator A5082418133 @default.
• W1878449863 creator A5091638762 @default.
• W1878449863 date "2015-01-01" @default.
• W1878449863 modified "2023-10-18" @default.
• W1878449863 title "EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas" @default.
• W1878449863 cites W1486290736 @default.
• W1878449863 cites W1504197144 @default.
• W1878449863 cites W1533713644 @default.
• W1878449863 cites W1874566015 @default.
• W1878449863 cites W1964292350 @default.
• W1878449863 cites W1965889264 @default.
• W1878449863 cites W1968863074 @default.
• W1878449863 cites W1969601801 @default.
• W1878449863 cites W1983688271 @default.
• W1878449863 cites W1985636377 @default.
• W1878449863 cites W1989923393 @default.
• W1878449863 cites W1993869441 @default.
• W1878449863 cites W2001619808 @default.
• W1878449863 cites W2005351392 @default.
• W1878449863 cites W2006952441 @default.
• W1878449863 cites W2014212444 @default.
• W1878449863 cites W2017421515 @default.
• W1878449863 cites W2024221132 @default.
• W1878449863 cites W2027948664 @default.
• W1878449863 cites W2034470404 @default.
• W1878449863 cites W2034661956 @default.
• W1878449863 cites W2040458067 @default.
• W1878449863 cites W2040898103 @default.
• W1878449863 cites W2045155806 @default.
• W1878449863 cites W2060147931 @default.
• W1878449863 cites W2064478922 @default.
• W1878449863 cites W2072932198 @default.
• W1878449863 cites W2075821278 @default.
• W1878449863 cites W2081548587 @default.
• W1878449863 cites W2081602975 @default.
• W1878449863 cites W2082716512 @default.
• W1878449863 cites W2084746694 @default.
• W1878449863 cites W2088684637 @default.
• W1878449863 cites W2091752769 @default.
• W1878449863 cites W2096287682 @default.
• W1878449863 cites W2100526290 @default.
• W1878449863 cites W2104423020 @default.
• W1878449863 cites W2120556344 @default.
• W1878449863 cites W2123783570 @default.
• W1878449863 cites W2128659329 @default.
• W1878449863 cites W2134807618 @default.
• W1878449863 cites W2135833883 @default.
• W1878449863 cites W2141431050 @default.
• W1878449863 cites W2143580218 @default.
• W1878449863 cites W2149432374 @default.
• W1878449863 cites W2155798001 @default.
• W1878449863 cites W2157800960 @default.
• W1878449863 cites W2160334406 @default.
• W1878449863 cites W2167501668 @default.
• W1878449863 cites W2294783710 @default.
• W1878449863 cites W2328946792 @default.
• W1878449863 cites W54096870 @default.
• W1878449863 doi "https://doi.org/10.18632/oncotarget.2745" @default.
• W1878449863 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4381601" @default.
• W1878449863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25621889" @default.
• W1878449863 hasPublicationYear "2015" @default.
• W1878449863 type Work @default.
• W1878449863 sameAs 1878449863 @default.
• W1878449863 citedByCount "22" @default.
• W1878449863 countsByYear W18784498632015 @default.
• W1878449863 countsByYear W18784498632016 @default.
• W1878449863 countsByYear W18784498632017 @default.
• W1878449863 countsByYear W18784498632018 @default.
• W1878449863 countsByYear W18784498632019 @default.
• W1878449863 countsByYear W18784498632020 @default.
• W1878449863 countsByYear W18784498632021 @default.
• W1878449863 countsByYear W18784498632022 @default.
• W1878449863 countsByYear W18784498632023 @default.
• W1878449863 crossrefType "journal-article" @default.
• W1878449863 hasAuthorship W1878449863A5013933481 @default.
• W1878449863 hasAuthorship W1878449863A5021788061 @default.
• W1878449863 hasAuthorship W1878449863A5026137617 @default.
• W1878449863 hasAuthorship W1878449863A5029195466 @default.
• W1878449863 hasAuthorship W1878449863A5037828387 @default.
• W1878449863 hasAuthorship W1878449863A5053377466 @default.
• W1878449863 hasAuthorship W1878449863A5059286400 @default.
• W1878449863 hasAuthorship W1878449863A5062071343 @default.
• W1878449863 hasAuthorship W1878449863A5063726212 @default.

• next